NEWS
June 2, 2010
Kuros completes patient recruitment in Phase IIb study of KUR-113 in patients with tibial shaft fractures
 
Study assessing the safety and efficacy of KUR-113 expected to report in H1 2011

Zurich, Switzerland, 2nd June 2010 - Kuros Biosurgery AG, a biotechnology company
focused on the development of novel biomaterials and bioactive-biomaterial combination
products for trauma, wound and spinal indications, announced today that it has completed
recruitment in a 200 patient Phase IIb clinical trial designed to assess the efficacy and safety
of KUR-113 (Viz.I-040202) in open tibial shaft fractures.

This study is a randomized, controlled, open-label (dose-blinded) dose finding study of the
safety and efficacy of KUR-113 in the treatment of patients with acute open tibial shaft
fractures. The aim of the trial is to assess the safety and efficacy of KUR-113 in combination
with standard of care (SOC) vs SOC alone. The use of KUR-113 is designed to improve
bone healing by reducing the time needed to achieve bone healing as well as the incidence
of secondary interventions.

KUR-113 utilizes Kuros’ “TG-hook” technology for binding proprietary biologics into a fibrin
sealant. The product candidate is composed of a variant of parathyroid hormone (vPTH) and
fibrin sealant and is applied directly to the fracture site in the form of a paste. KUR-113 has
been designed to deliver vPTH locally at the fracture site and to maintain this via the slow
controlled release of vPTH over time from the fibrin matrix. The fibrin matrix also plays a
further important role in the bone healing process by providing a physical scaffold for cell
ingrowth. The trial will assess whether this approach is safe and efficacious.

A total of 200 patients have been randomized and treated in over 31 centers across Europe.
The primary endpoint of this study is the proportion of patients healed at 6 months after
surgery when compared to SOC alone. Kuros is expecting to report the outcome of this study
in the first half of 2011.

Dr. Virginia Jamieson, Chief Medical Officer of Kuros, commented: “We are very pleased to
have completed recruitment for this study with KUR-113 and we look forward to reporting the
results of this novel approach to the treatment of open tibial shaft fractures in the first half of
2011.”

KUR-113 is licensed to Baxter International Inc. under a collaboration and license agreement
which was signed in 2005. Following the successful completion of this study, Baxter will take
over responsibility for the further development of KUR-113.

Didier Cowling, Chief Executive Officer of Kuros, commented: “Completion of patient
recruitment in this large Phase IIb study is another significant step for Kuros. We look
forward to broadening the application of this technology to additional orthopedic settings”.


About tibial shaft fractures

The tibia is the major bone between the knee and ankle, often referred to as the shin bone.
Fractures of the tibial shaft are the most common long-bone fractures treated by an
orthopedic surgeon. They are generally regarded as difficult to treat due to the risk of nonunion
and other secondary complications. Improving the healing rate and reducing the
incidence of secondary complications is therefore of great importance to these patients.


About Kuros
www.kuros.ch

Kuros is a biotechnology company that is focused on the development of novel biomaterials
and bioactive-biomaterial combinations for trauma, wound and spinal indications.

Kuros’ combination products are designed to mimic the body’s natural healing process. The
products consist of fusion proteins of naturally occurring bioactive factors, covalently
incorporated into fibrin or synthetic matrices. The incorporation of the biologically active
molecules into the injectable matrices aims to maximize their activity by retention at the site
of action. Kuros products are designed to combine ease of application with localized delivery.
Kuros has a number of methodologies to achieve the desired retention and release profiles
of the biologically active molecules.

Kuros’ has a diverse pipeline of product candidates with its most advanced products being in
trauma and wound care.

Since its creation in 2000, Kuros has raised over $100 million. The company is located in
Zurich, Switzerland.


Press Enquiries

Kuros
Didier Cowling, CEO +41 (0)44 200 56 62
Alistair Irvine, Director of Business Development +41 (0)44 200 56 62

For Swiss Media Enquires:
The IRF Communications
Martin Meier-Pfister +41 (0)43 244 81 40
Jan Gregor +41 (0)43 244 81 54

For International Media Enquires:
Citigate Dewe Rogerson
David Dible, Amber Bielecka, Nina Enegren +44 (0)207 638 9571

back
partner of the European Tech Tour "Endeavour Vision's team brought an in-depth knowledge of our field – highlighted by impressive and thorough 360° due diligence, the long-term perspective required to build substantial companies, outstanding experience of bringing venture to financial success and an uncommon sense for team work. This is "smart money" at its best."
Jacques R. Essinger, CEO Symetis